. But, according to Brook Baker, a professor of law at Northeastern University who has tracked the negotiations over the drug, the price of a course of treatment could fall below $10 as competition increases among manufacturers and production scale grows.
“We had a responsibility,” she added. “You could not have a capsule and not be able to find a way to get it across the world.”Molnupiravir has yet to receive approval from either U.S. or European regulators. Merck applied to the U.S. Food and Drug Agency for emergency use authorization this month and the European Medicines Agency recently began a rolling review of the drug.But experts say that it has huge potential to fight the pandemic.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: